HAWTHORNE, N.Y., June 1, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for ammonium lactate lotion, 12%.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 29, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO): First Quarter Highlights -- Sales of $84.1 Million Reflect a 22% Increase Over First Quarter of 2003 -- Gross Profit Increases 27% to $56.4 Million, or 67% of Sales -- Increased Marketing Expenses
HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 28, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) intends to report financial results for the first quarter of 2004 prior to the Nasdaq market opening on Thursday, April 29, 2004. The Company will conduct a conference call to discuss the results on
HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 7, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for terconazole vaginal cream, 0.8%.
HAWTHORNE, N.Y., Mar 8, 2004 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Phenytoin Oral Suspension USP, 125
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb. 17, 2004-- 20 Consecutive Years of Record Sales; 6 Consecutive Years of Record Net Income 2003 Highlights -- Q4 Sales Increase 43% to $88.6 million -- Q4 Gross Profit Increases 61% to $62.1 million -- Q4 Net Income Increases 29% to $16.6 million, or $0.56 per
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 8, 2004-- OTC Formulation Extends Line of Spill-Resistant ElixSure(TM) Pediatric Products Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that its U.S. affiliate has received approval from the U.S.
Hawthorne, New York, January 8, 2004 – Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) today announced that its U.S. affiliate has expanded its distribution capacity with the purchase of a modern, 315,000 square foot distribution center on 25 acres of land in South Brunswick, New Jersey.
HAWTHORNE, N.Y., Dec 10, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) today announced that ElixSure(TM) spill-resistant children's medicines, recently launched in the U.S. by Taro Consumer Healthcare Products, have received a 2003 Good Buy Award from the Good
HAWTHORNE, N.Y., Dec 9, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) reported today that its U.S. affiliate has received approvals from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Applications ("ANDAs") for betamethasone dipropionate